Tsutom Tokashiki
Director/Board Member at NOILE-IMMUNE BIOTECH INC.
Network origin in Tsutom Tokashiki first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Tsutom Tokashiki via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
GlaxoSmithKline KK
 GlaxoSmithKline KK Household/Personal CareConsumer Non-Durables GlaxoSmithKline KK researches, develops, imports, manufactures and sells toiletry products. The company was founded on August 18, 1928 and is headquartered in Tokyo, Japan | Household/Personal Care | President | |
4BIO Ventures Management Ltd.
 4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
| REZOLUTE, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Université Paris Nanterre | College/University | Undergraduate Degree | |
Sanofi-Aventis Groupe SA
 Sanofi-Aventis Groupe SA Financial ConglomeratesFinance Sanofi-Aventis Groupe SA operates as a holding company, with interest in the manufacture and distribution of pharmaceutical products. The company was founded on December 19, 1995 and is headquartered in Paris, France. | Financial Conglomerates | Corporate Officer/Principal | |
| JCR PHARMACEUTICALS CO., LTD. | Pharmaceuticals: Major | Director/Board Member | |
| École des Hautes Études Commerciales de Paris | College/University | Graduate Degree | |
Luca Science, Inc.
 Luca Science, Inc. BiotechnologyHealth Technology Luca Science, Inc. is a Japanese preclinical stage biopharmaceutical company that specializes in mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs. Luca Science is based in Chuo-ku, JP, and was founded in December 2018 by Masashi Suganuma. The company uses its platform technology to manufacture, store, and deliver innovative mitochondrial drugs to research and develop therapeutics for unmet medical needs in a wide range of diseases for which there have been no effective treatments. The CEO is Rick C. Tsai. | Biotechnology | Director/Board Member | |
| Yamaguchi University | College/University | Corporate Officer/Principal |
Statistics
International
| Japan | 5 |
| France | 4 |
| United Kingdom | 2 |
| United States | 2 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 4 |
| Finance | 3 |
| Consumer Non-Durables | 2 |
Operational
| Director/Board Member | 7 |
| President | 2 |
| Independent Dir/Board Member | 2 |
| Corporate Officer/Principal | 2 |
| Chairman | 1 |
Most connected contacts
| Insiders | |
|---|---|
| Philippe Fauchet | 9 |
| Koji Tamada | 2 |
| Hiroko Nagai | 1 |
- Stock Market
- Insiders
- Tsutom Tokashiki
- Company connections
